Role of the modulation of CYP1A1 expression and activity in chemoprevention

Journal of Applied Toxicology - Tập 34 Số 7 - Trang 743-753 - 2014
Simone Badal1, Rupika Delgoda1
1Natural Products Institute, Faculty of Science and Technology University of the West Indies Mona Kingston 7 Jamaica, West Indies

Tóm tắt

ABSTRACT

As one of the main extra‐hepatic cytochrome P450 (CYP) enzymes, CYP1A1 has been comprehensively investigated for its ability to metabolize both exogenous and endogenous compounds into their carcinogenic derivatives. These derivatives are linked to cancer initiation and progression. The compound benzo‐a‐pyrene (BaP), a copious and noxious compound present in coal tar, automobile exhaust fumes, cigarette smoke and charbroiled food, is metabolised by CYP1A1 and has been studied in great detail. Other compounds reliant on the same enzyme for their activation include 7,12 dimethylbenz(a)anthracene (DMBA) and heterocyclic amine, 2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine (PhIP). This review takes an in‐depth look at a number of phytochemicals, plant extracts and a few synthetic compounds that have been researched and deemed potential chemopreventives via their interaction with the activity and expression of CYP1A1. It will also review a useful active site model of CYP1A1. Based on inhibitors of CYP1A1 that have demonstrated in vivo use as chemopreventors, CYP1A1 is a useful initial target for screening compounds with such potential, with the use of rapid in vitro and/or in silico assessments. Chemoprevention is a means by which healthy tissues are protected via the prevention, inhibition or reversal of carcinogenesis. This review focuses on one important pathway of carcinogenesis and identifies the important role that CYP1A1 plays in that pathway. It is hoped that highlighting the importance of such a key target, will help revive further research into and application of inhibitors of CYP1A1 towards generating improved chemopreventors. Copyright © 2014 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1016/j.urolonc.2011.12.009

10.1016/j.bmc.2011.03.042

Androutsopoulos V, 2009, Cytochrome P450 Cyp1a1: Wider Roles in Cancer Progression and Prevention, Biomed. Central Cancer, 9, 187

10.1016/S1734-1140(10)70311-X

10.1186/2191-2858-2-21

10.1016/j.fitote.2010.10.003

10.1093/toxsci/kfp079

10.1038/sj.bjc.6602125

10.3736/jcim20100708

10.1016/j.bcp.2006.01.017

Bourrié M, 1996, Cytochrome P450 Isoform Inhibitors as a Tool for the Investigation of Metabolic Reactions Catalyzed by Human Liver Microsomes, JPET, 277, 321

Buterin T, 2000, Unrepaired Fjord Region Polycyclic Aromatic Hydrocarbon‐DNA Adducts in Ras Codon 61 Mutational Hot Spots, Cancer Res., 60, 1849

Callero M, 2012, Aryl Hydrocarbon Receptor Activation by Aminoflavone: New Molecular Target for Renal Cancer Treatment, Int. J. Oncol., 41, 125

Chabner B, 1991, Anti‐Cancer Drugs, Principles and Practice

Chabner B, 1996, The Pharmacological Basis of Therapeutics, 1233

10.1021/jf1014439

10.1016/j.taap.2005.09.007

10.1016/S0021-9258(18)47020-2

10.1021/tx00011a011

10.1007/s11373-005-9028-8

10.1006/bbrc.1999.1152

10.1016/S0006-2952(98)00143-9

Ciolino H, 1998, Resveratrol Inhibits Transcription of Cyp1a1 in Vitro by Preventing Activation of the Aryl Hydrocarbon Receptor, Cancer Res., 58, 5707

10.1042/bj3400715

10.1038/sj.bjc.6690216

Coon M, 1996, Peroxidative Reactions of Diversozymes, FASEB J., 10, 428, 10.1096/fasebj.10.4.8647341

10.1379/1466-1268(2004)009<0004:COHSPA>2.0.CO;2

10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V

10.1093/carcin/15.12.2961

10.1146/annurev.pharmtox.43.100901.140251

10.1016/S0300-483X(99)00215-2

Easton D, 1995, Breast and Ovarian Cancer Incidence in Brca1‐Mutation Carriers, Am. J. Hum. Genet., 56, 265

10.1016/j.toxlet.2011.09.030

10.1021/np800098f

10.1016/S0140-6736(94)91578-4

10.1086/301749

10.1017/S0007114507725151

10.1093/carcin/22.3.367

Hakkak R, 2000, Diets Containing Whey Proteins or Soy Protein Isolate Protect against 7,12‐Dimethylbenz(a)Anthracene‐Induced Mammary Tumors in Female Rats, Cancer Epidemiol. Biomarkers Prev., 9, 113

Hamid A, 2011, Recent Role of Inflammation in Prostate Diseases: Chemoprevention Development Opportunity, Acta Med. Indones‐Indones J. Intern. Med., 43, 59

10.1248/bpb.29.1310

10.1126/science.7997877

10.1016/S0098-2997(99)00005-9

10.1093/jnci/91.14.1194

10.1016/j.fct.2009.12.019

10.1158/1940-6207.CAPR-08-0149

IARC.2010.Agents Classified by the Iarc Monographs2010 [cited 1–100]. http://monographs.iarc.fr/ENG/Classification/ClassificationsAlphaOrder.pdf.

10.1073/pnas.97.17.9603

10.1016/j.toxlet.2013.01.020

10.1093/carcin/18.1.107

10.1007/s00394-006-0620-0

10.1093/carcin/19.10.1847

10.1177/0748233713475524

Klassenn D, 2001, Casarette and Doull's Toxicology: The Basic Science of Poisons, 107

10.1021/ja00437a061

10.1210/en.2003-0192

10.1093/toxsci/58.2.235

10.1080/15287390490514642

10.3727/096504008786111365

10.1016/j.tiv.2007.04.005

10.1016/j.abb.2007.09.014

10.1016/j.abb.2007.09.014

10.1021/jf104653n

10.1021/jf0624796

10.1021/tx300023p

10.1093/carcin/bgl184

10.1124/dmd.104.002410

MacDonald C, 2001, Dibenzoylmethane Modulates Aryl Hydrocardon Receptor Function and Expression of Cytochromes P450 1a1, 1a2 and 1b1, Cancer Res., 61, 3919

10.1093/jnci/82.16.1333

10.1128/MCB.18.2.978

10.1126/science.7545954

10.1002/mnfr.200600135

10.1021/tx300169e

10.1158/1940-6207.CAPR-12-0002

10.1007/s11130-012-0304-2

10.1016/j.tiv.2004.11.003

10.1074/jbc.R400004200

10.1097/00008571-199602000-00002

10.1146/annurev.bi.61.070192.002301

10.1038/2594

10.1002/ptr.2762

10.1124/mol.107.039826

10.1016/j.fct.2012.05.058

10.1080/00498250701713968

10.1038/sj.onc.1205803

10.1006/abbi.1998.0814

10.1016/S0024-3205(03)00420-X

10.1093/carcin/bgl118

10.1016/j.toxlet.2005.06.002

10.1124/mol.53.3.438

10.1002/jat.916

Rinaldi A, 2002, Curcumin Activates the Aryl Hydrocarbon Receptor yet Significantly Inhibits (‐)‐Benzo(a)Pyrene‐7r‐Trans‐7,8‐Dihydrodiol Bioactivation in Oral Squamous Cell Carcinoma Cells and Oral Mucosa, Cancer Res., 62, 5451

10.1002/ptr.2613

10.1016/j.canlet.2003.11.016

10.1093/jn/131.12.3281

10.1073/pnas.87.10.3826

10.1016/S0960-0760(03)00390-X

10.1006/bbrc.1996.1785

10.1016/j.jep.2009.10.030

10.1074/jbc.M611692200

10.1093/carcin/20.12.2279

10.1200/JCO.2005.01.5594

10.1016/j.bcp.2003.12.023

Schwarz D, 2003, St. John's Wort Extracts and Some of Their Constituents Potently Inhibit Ultimate Carcinogen Formation from Benzo[a]Pyrene‐7,8‐Dihydrodiol by Human Cyp1a1, Cancer Res., 15, 8062

10.1016/S0006-291X(03)00435-2

10.1038/sj.onc.1200881

10.1055/s-0028-1088350

10.1073/pnas.86.2.462

Shimada T, 1989, Roles of Individual Human Cytochrome P‐450 Enzymes in the Bioactivation of Benzo[a]Pyrene, 7,8‐Dihydroxy‐7,8‐Dihydrobenzo[a]Pyrene. And Other Dihydrodiol Derivatives of Polycyclic Aromatic Hydrocarbons, Cancer Res., 49, 6304

10.1073/pnas.97.2.779

10.1021/bi970541

10.1093/carcin/bgm288

10.1016/j.mrgentox.2007.03.009

10.1111/j.1365-2265.2007.03108.x

10.1289/ehp.97105s4945

10.1016/j.bmc.2010.07.020

10.1016/j.tox.2010.09.002

10.1016/S0278-6915(00)00165-4

10.1016/S0140-6736(98)03300-5

Treasure J, 2000, Herbal Pharmacokinetics: A Practitioner Update with Reference to St. Johns Wort (Hypericum Perforatum) Herb‐Drug Interactions, MNIMH, 1, 6

10.1038/nm1087

10.1016/j.toxlet.2004.03.005

10.1074/jbc.M113.452953

10.1016/j.ejphar.2008.10.057

Wei O, 1996, Benzo (a) Pyrene Diol Epoxide‐Induced Chromosomal Aberrations and Risk of Lung Cancer, Cancer Res., 56, 3975

10.1126/science.959820

WHO, 2013, Cancer

10.1165/ajrcmb.17.1.2783

10.1016/S0009-2797(00)00204-0

10.1038/378789a0

Yarbro J, 1992, The Scientific Basis of Cancer Chemotherapy, The Chemotherapy Source Book

10.1248/bpb.33.1650

10.1016/j.cbpc.2011.07.005